Bracco and ACIST Medical Systems Announce U.S. FDA Clearance of ACIST Pro™ Diagnostic System

May 18, 2026

ACIST Medical Systems, Inc., a Bracco company and a global leader in advanced contrast management technologies, has announced that its ACIST Pro™ Diagnostic System has received clearance from the U.S. Food and Drug Administration (FDA). The system is being launched in the United States as a next-generation variable-rate contrast management solution.

The ACIST Pro™ Diagnostic System aims to enhance precision, safety, and efficiency in image-guided cardiovascular procedures. This innovative technology is positioned to streamline interventional cardiology procedures by providing precise contrast control.

This launch marks a significant advancement in the field of cardiovascular care and highlights ACIST Medical Systems' commitment to improving patient outcomes through technological innovation.

Disclaimer: This press release has been distributed on behalf of the issuing organization. PR Gun acts solely as a distribution platform and has not independently verified the accuracy, completeness, or validity of the statements contained herein.